A python's embrace? Insurance and the global clinical trial

Area of Science:

• Health Policy
• Clinical Trial Management
• Global Health Security

Background:

• Regulatory barriers impede clinical trial approvals, particularly for multi-country academic trials and those in low- and middle-income countries (LMICs).
• Clinical trial insurance, a critical component of trial oversight, has been largely overlooked in analyses of regulatory efficiency and ethical frameworks.
• Existing literature often uses metaphors like a "python's embrace" to describe regulatory hurdles but fails to detail the specific impact of insurance.

Purpose of the Study:

• To analyze the evolution of clinical trial indemnification mechanisms over the past 50 years.
• To investigate procedural barriers in multi-country clinical research, using the COVID-19 pandemic and a specific case study.
• To identify how insurance requirements impact trial site initiation in LMICs.

Main Methods:

• Structured literature review of clinical trial indemnification mechanisms.
• Case study analysis of the University of Oxford's "COPCOV" trial, including thematic analysis of over 65 stakeholder interviews.
• Examination of insurance documents and stakeholder communications.

Main Results:

• Supplementary reinsurance for the COPCOV trial exceeded £110,000 and caused up to nine-month delays in country approvals.
• Sponsors cited reputational damage concerns as justification for costly insurance policies.
• The expansion of financial risk management frameworks and local insurance requirements creates substantial barriers for initiating trial sites in LMICs.

Conclusions:

• Two reform pathways—procedural and systemic—are proposed to address barriers in clinical trial insurance.
• Reforms should be spearheaded by policymakers within LMICs to ensure relevance and effectiveness.
• Streamlining insurance procedures is crucial for timely availability of evidence on efficacious countermeasures during global health emergencies.